Negative sentiment towards CARM reflected by a jump of 64.24% in short interest

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Carisma Therapeutics Inc shares valued at $14,485 were sold by Klichinsky Michael on Oct 07 ’25. At $0.25 per share, Klichinsky Michael sold 56,982 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.

Also, MICHAEL KLICHINSKY purchased 56,982 shares, netting a total of over 14,183 in proceeds.

Before that, Klichinsky Michael had sold 200,000 shares from its account. In a trade valued at $50,860, the Chief Scientific Officer traded Carisma Therapeutics Inc shares for $0.25 each. Upon closing the transaction, the insider’s holdings decreased to 200,000 shares, worth approximately $32223.690000000002.

As published in a research note from Robert W. Baird on December 12, 2024, Carisma Therapeutics Inc [CARM] has been rated down from an Outperform to a Neutral and the price target has been revised to $1 from $10. Analysts at BTIG Research downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early December. As of April 11, 2024, BTIG Research has initiated its “Buy” rating for CARM. Earlier on October 03, 2023, CapitalOne initiated its rating. Their recommendation was “an Overweight” for CARM stock.

Analyzing CARM Stock Performance

On last trading session, Carisma Therapeutics Inc [NASDAQ: CARM] rose 2.90% to $0.27. The stock’s lowest price that day was $0.26, but it reached a high of $0.2888 in the same session. During the last five days, there has been a surge of approximately 5.47%. Over the course of the year, Carisma Therapeutics Inc shares have dropped approximately -71.43%. Shares of the company reached a 52-week high of $1.2700 on 06/10/25 and a 52-week low of $0.1417 on 05/16/25.

Support And Resistance Levels for Carisma Therapeutics Inc (CARM)

According to the 24-hour chart, there is a support level at 0.2570, which, if violated, would cause prices to drop to 0.2440. In the upper region, resistance lies at 0.2859. The next price resistance is at 0.3018. RSI (Relative Strength Index) is 45.51 on the 14-day chart, showing neutral technical sentiment.

Is Carisma Therapeutics Inc subject to short interest?

Stocks of Carisma Therapeutics Inc saw a sharp rise in short interest on 2025-09-15 jumping by 1.01 million shares to 1.57 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 0.56 million shares. A jump of 64.24% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.06 of the overall float, the days-to-cover ratio (short ratio) jumped to 0.06.

Which companies own the most shares of Carisma Therapeutics Inc (CARM)?

In terms of Carisma Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 6 in the next 12 months, up nearly 2207.69% from the previous closing price of $0.26. Analysts anticipate Carisma Therapeutics Inc stock to reach 6 by 2025, with the lowest price target being 6. In spite of this, 2 analysts ranked Carisma Therapeutics Inc stock as Buy at the end of 2025. On July 06, 2023, Evercore ISI assigned a price target of “an Outperform” to the stock and initiated coverage with a $12.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.